ARO-ALK7

PreclinicalSmall molecule

Arrowhead Pharmaceuticals

ARO-ALK7 is one of 67 small molecule programs targeting Type 2 Diabetes Mellitus. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Type 2 Diabetes MellitusActive, not recruiting

ObesityRecruiting

Type 2 Diabetes MellitusPhase 1/Phase 2

Active, not recruiting

ObesityPreclinical

Recruiting

Competition

Competitive Landscape

676 competitors in Type 2 Diabetes Mellitus

#DrugCompanyPhaseTrials

Tanzeum

GSK

Preclinical

10 2

Insulin 320

Novo Nordisk

Preclinical

43 3

NOVOLIN R

Novo Nordisk

Preclinical

1 4

Adenocard

Astellas

Preclinical

1 5

Dostinex

Golytely

Cipro

Myrbetriq

Lantus

6 10

Lixisenatide

Sanofi

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

PreclinicalRecruiting

Obesity

NCT06937203

Clinical

Trials by Indication[1]

Obesity1 trial

A Phase 1/2A Dose-Escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ARO-ALK7 in Adult Volunteers With Obesity With and Without Type 2 Diabetes Mellitus

Recruiting· Arrowhead Pharmaceuticals logo

Arrowhead Pharmaceuticals·Preclinical·NCT06937203·150 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for ARO-ALK7. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ARO-ALK7 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ARO-ALK7. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Arrowhead Pharmaceuticals company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: Arrowhead Pharmaceuticals

ARO-ALK7

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

Obesity1 trial

References

Drug Info

Quick Facts

Related News